Business
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic disea
About this update from Pliant Therapeutics, Inc.
[{"type":"image","alt":"Pliant Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pliant Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/edb2ca8d16c72c342dd4b7660bdebe5e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0ysHvIhQdh.4yF4UgalK7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/edb2ca8d16c72c342dd4b7660bdebe5e","width":300,"height":300}},"lazy":false},{"type":"text","content":"Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025","length":116,"tagName":"p"},{"type":"text","content":"Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials","length":148,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results.","length":333,"tagName":"p"},{"type":"text","content":"“During the first quarter and over recent weeks, our teams have been working diligently to close out the global BEACON-IPF trial with the goal of announcing topline data in the second quarter,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “Additionally, progress was made in our oncology program with initial data from our Phase 1 dose escalation trial of PLN-101095 demonstrating antitumor activity, including confirmed partial responses, in a variety of solid tumors.”","length":508,"tagName":"p"},{"type":"text","content":"First Quarter and Recent Developments","length":37,"tagName":"p"},{"type":"text","content":"Bexotegrast Highlights","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BEACON-IPF close-out activities continue with topline data expected in the second quarter of 2025. Following the termination of the BEACON-IPF Phase 2b/3 trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), the Company continues the formal close out of the global tria...